Cardiol Therapeutics Inc. (CRDL)
USD 1.34
(-2.19%)
USD 1.34
(-2.19%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.45 Million CAD | -13.97% |
| 2022 | 9.82 Million CAD | -15.56% |
| 2021 | 11.63 Million CAD | 343.72% |
| 2020 | 2.62 Million CAD | 215.69% |
| 2019 | 830.82 Thousand CAD | -65.53% |
| 2018 | 2.41 Million CAD | 557.28% |
| 2017 | 366.75 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 10.95 Million CAD | -1.04% |
| 2024 Q1 | 11.06 Million CAD | 30.91% |
| 2023 Q4 | 8.45 Million CAD | 3.32% |
| 2023 Q2 | 8.41 Million CAD | 18.08% |
| 2023 Q1 | 7.12 Million CAD | -27.45% |
| 2023 FY | 8.45 Million CAD | -13.97% |
| 2023 Q3 | 8.18 Million CAD | -2.81% |
| 2022 Q2 | 11.41 Million CAD | 11.69% |
| 2022 Q3 | 9.68 Million CAD | -15.17% |
| 2022 FY | 9.82 Million CAD | -15.56% |
| 2022 Q1 | 10.21 Million CAD | -12.2% |
| 2022 Q4 | 9.82 Million CAD | 1.5% |
| 2021 Q1 | 2.85 Million CAD | 9.01% |
| 2021 FY | 11.63 Million CAD | 343.72% |
| 2021 Q4 | 11.63 Million CAD | 339.81% |
| 2021 Q3 | 2.64 Million CAD | -12.15% |
| 2021 Q2 | 3.01 Million CAD | 5.35% |
| 2020 Q1 | 826.44 Thousand CAD | -0.53% |
| 2020 FY | 2.62 Million CAD | 215.69% |
| 2020 Q4 | 2.62 Million CAD | 32.3% |
| 2020 Q3 | 1.98 Million CAD | 50.86% |
| 2020 Q2 | 1.31 Million CAD | 59.01% |
| 2019 Q3 | 1.65 Million CAD | 74.54% |
| 2019 Q2 | 950.08 Thousand CAD | -2.73% |
| 2019 Q1 | 976.78 Thousand CAD | -59.48% |
| 2019 FY | 830.82 Thousand CAD | -65.53% |
| 2019 Q4 | 830.82 Thousand CAD | -49.9% |
| 2018 Q4 | 2.41 Million CAD | -85.21% |
| 2018 FY | 2.41 Million CAD | 557.28% |
| 2018 Q1 | - CAD | -100.0% |
| 2018 Q2 | 11.21 Million CAD | 0.0% |
| 2018 Q3 | 16.3 Million CAD | 45.31% |
| 2017 FY | 366.75 Thousand CAD | 0.0% |
| 2017 Q4 | 366.75 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Theratechnologies Inc. | 98.63 Million USD | 91.429% |
| Harrow Health, Inc. | 241.75 Million USD | 96.503% |
| Dynavax Technologies Corporation | 375.02 Million USD | 97.746% |
| Biofrontera Inc. | 23.13 Million USD | 63.464% |
| Cronos Group Inc. | 43.73 Million USD | 80.67% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 3.449% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 98.966% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 82.549% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 59.701% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 83.902% |
| Radius Health, Inc. | 804.29 Million USD | 98.949% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 38.536% |
| DURECT Corporation | 30.4 Million USD | 72.196% |
| ProPhase Labs, Inc. | 42.54 Million USD | 80.129% |
| Safety Shot Inc | 3.89 Million USD | -117.212% |
| Phibro Animal Health Corporation | 725.54 Million USD | 98.835% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 8.075% |
| Alvotech | 1.88 Billion USD | 99.551% |
| Assertio Holdings, Inc. | 148.41 Million USD | 94.304% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 98.266% |
| Rockwell Medical, Inc. | 30.88 Million USD | 72.625% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -37.696% |
| Procaps Group S.A. | 462.06 Million USD | 98.17% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 93.823% |
| SCYNEXIS, Inc. | 55.45 Million USD | 84.754% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 90.646% |
| Viatris Inc. | 27.21 Billion USD | 99.969% |
| OptiNose, Inc. | 194.33 Million USD | 95.65% |
| SIGA Technologies, Inc. | 57.97 Million USD | 85.418% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.052% |
| PetIQ, Inc. | 645.22 Million USD | 98.69% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -37.696% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.171% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -124.117% |
| Alimera Sciences, Inc. | 107.35 Million USD | 92.125% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.108% |
| Silver Spike Investment Corp. | 3 Million USD | -180.88% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -345.894% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 95.339% |
| Journey Medical Corporation | 56.49 Million USD | 85.037% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 60.339% |
| Alpha Teknova, Inc. | 38.55 Million USD | 78.071% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -20.325% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 96.154% |
| PainReform Ltd. | 2.69 Million USD | -214.158% |
| Cosmos Health Inc. | 30.25 Million USD | 72.055% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 95.124% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 39.709% |
| Embecta Corp. | 2.03 Billion USD | 99.585% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -3751.271% |
| Talphera, Inc. | 6.29 Million USD | -34.404% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 98.8% |
| Incannex Healthcare Limited | 5.83 Million USD | -45.009% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 0.43% |
| Shineco, Inc. | 47.6 Million USD | 82.24% |
| Procaps Group, S.A. | 462.06 Million USD | 98.17% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 98.208% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 94.842% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 98.988% |
| Alvotech | 1.88 Billion USD | 99.551% |
| Hempacco Co., Inc. | 18.82 Million USD | 55.085% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 95.102% |
| Bright Green Corporation | 6.43 Million USD | -31.312% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 98.721% |
| Kamada Ltd. | 109.96 Million USD | 92.312% |
| Indivior PLC | 1.95 Billion USD | 99.567% |
| Evoke Pharma, Inc. | 9.64 Million USD | 12.376% |
| Flora Growth Corp. | 17.22 Million USD | 50.912% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 0.43% |
| Evolus, Inc. | 209.68 Million USD | 95.968% |
| HUTCHMED (China) Limited | 536.38 Million USD | 98.424% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.032% |
| Akanda Corp. | 12.66 Million USD | 33.27% |